Gilead Sciences Inc - Net Worth and Insider Trading

Gilead Sciences Inc Net Worth

The estimated net worth of Gilead Sciences Inc is at least $514 Million dollars as of 2024-11-29. Gilead Sciences Inc is the 10% Owner of Arcus Biosciences Inc and owns about 30,061,124 shares of Arcus Biosciences Inc (RCUS) stock worth over $475 Million. Gilead Sciences Inc is the 10% Owner of Kyverna Therapeutics Inc and owns about 4,126,119 shares of Kyverna Therapeutics Inc (KYTX) stock worth over $22 Million. Gilead Sciences Inc is also the 10% Owner of AlloVir Inc and owns about 16,635,286 shares of AlloVir Inc (ALVR) stock worth over $9 Million. Besides these, Gilead Sciences Inc also holds Xilio Therapeutics Inc (XLO) . Details can be seen in Gilead Sciences Inc's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Gilead Sciences Inc has not made any transactions after 2024-04-02 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Gilead Sciences Inc

To

Gilead Sciences Inc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Gilead Sciences Inc owns 6 companies in total, including Jounce Therapeutics Inc (JNCE) , Arcus Biosciences Inc (RCUS) , and Achillion Pharmaceuticals Inc (ACHN) among others .

Click here to see the complete history of Gilead Sciences Inc’s form 4 insider trades.

Insider Ownership Summary of Gilead Sciences Inc

Ticker Comapny Transaction Date Type of Owner
JNCE Jounce Therapeutics Inc 2020-10-16 10 percent owner
RCUS Arcus Biosciences Inc 2024-01-29 10 percent owner
ACHN Achillion Pharmaceuticals Inc 2006-10-31 10 percent owner
LIMIT LIMIT 2022-02-15 10 percent owner
LIMIT LIMIT 2023-06-27 10 percent owner
LIMIT LIMIT 2023-10-16 10 percent owner

Gilead Sciences Inc Latest Holdings Summary

Gilead Sciences Inc currently owns a total of 4 stocks. Among these stocks, Gilead Sciences Inc owns 30,061,124 shares of Arcus Biosciences Inc (RCUS) as of January 29, 2024, with a value of $475 Million and a weighting of 92.44%. Gilead Sciences Inc owns 4,126,119 shares of Kyverna Therapeutics Inc (KYTX) as of February 12, 2024, with a value of $22 Million and a weighting of 4.36%. Gilead Sciences Inc also owns 16,635,286 shares of AlloVir Inc (ALVR) as of June 27, 2023, with a value of $9 Million and a weighting of 1.75%. The other 1 stocks Xilio Therapeutics Inc (XLO) have a combined weighting of 1.44% among all his current holdings.

Latest Holdings of Gilead Sciences Inc

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
RCUS Arcus Biosciences Inc 2024-01-29 30,061,124 15.80 474,965,759
KYTX Kyverna Therapeutics Inc 2024-02-12 4,126,119 5.43 22,404,826
ALVR AlloVir Inc 2023-06-27 16,635,286 0.54 8,996,363
XLO Xilio Therapeutics Inc 2024-04-02 7,345,473 1.01 7,418,928

Holding Weightings of Gilead Sciences Inc


Gilead Sciences Inc Form 4 Trading Tracker

According to the SEC Form 4 filings, Gilead Sciences Inc has made a total of 3 transactions in Arcus Biosciences Inc (RCUS) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Arcus Biosciences Inc is the acquisition of 15,238,095 shares on January 29, 2024, which cost Gilead Sciences Inc around $320 Million.

According to the SEC Form 4 filings, Gilead Sciences Inc has made a total of 1 transactions in Kyverna Therapeutics Inc (KYTX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Kyverna Therapeutics Inc is the acquisition of 910,000 shares on February 12, 2024, which cost Gilead Sciences Inc around $20 Million.

According to the SEC Form 4 filings, Gilead Sciences Inc has made a total of 1 transactions in AlloVir Inc (ALVR) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in AlloVir Inc is the acquisition of 2,930,870 shares on June 27, 2023, which cost Gilead Sciences Inc around $11 Million.

More details on Gilead Sciences Inc's insider transactions can be found in the Insider Trading History of Gilead Sciences Inc table.

Insider Trading History of Gilead Sciences Inc

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Gilead Sciences Inc Trading Performance

GuruFocus tracks the stock performance after each of Gilead Sciences Inc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Gilead Sciences Inc is -22.46%. GuruFocus also compares Gilead Sciences Inc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Gilead Sciences Inc within 3 months outperforms 0 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Gilead Sciences Inc's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Gilead Sciences Inc

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 3 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -3.21 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -5.69 LIMIT LIMIT LIMIT LIMIT LIMIT

Gilead Sciences Inc Ownership Network

Ownership Network List of Gilead Sciences Inc

No Data

Ownership Network Relation of Gilead Sciences Inc

Insider Network Chart

Gilead Sciences Inc Owned Company Details

What does Jounce Therapeutics Inc do?

Who are the key executives at Jounce Therapeutics Inc?

Gilead Sciences Inc is the 10 percent owner of Jounce Therapeutics Inc. Other key executives at Jounce Therapeutics Inc include 10 percent owner Concentra Merger Sub, Inc. , 10 percent owner Concentra Biosciences, Llc , and director & CEO and President Richard /ca/ Murray .

Jounce Therapeutics Inc (JNCE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Jounce Therapeutics Inc (JNCE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Jounce Therapeutics Inc (JNCE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Jounce Therapeutics Inc (JNCE)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Jounce Therapeutics Inc Insider Transactions

No Available Data

Gilead Sciences Inc Mailing Address

Above is the net worth, insider trading, and ownership report for Gilead Sciences Inc. You might contact Gilead Sciences Inc via mailing address: 333 Lakeside Dr, Foster City Ca 94404.

Discussions on Gilead Sciences Inc

No discussions yet.